Top Stories
SCY-247, a second-generation triterpenoid antifungal, has shown in vitro activity against drug-resistant fungal pathogens.
Tolerance thinks the anti–IL-33 mAb could preserve thymic function and enhance immune resilience.
The deal for the preclinical molecular glue KRAS G12D (ON) inhibitor, dubbed SPR2015, is potentially worth over $2 billion.
Rights to the anti-latent myostatin sweeping antibody will return to Chugai Pharmaceutical.
In the BRAVE-AA-PEDS study, 42.4% of patients achieved a Severity of Alopecia Tool (SALT) score ≤20 at week 36.
Conference News
Two out of the three antibody-drug conjugates (ADC) featured in Merck & Co. and Daiichi Sankyo's $4-billion partnership have now taken regulatory hits — and their shared deruxtecan payload has already absorbed a third. But the ADC damage isn't limited to deruxtecan.
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development ...
New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areataCompany to host conference call with investors a...
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeuti...
NextCell Pharma AB (publ) (“NextCell” or the “Company”) has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection ...
